New daily shot could tame severe MG attacks

NCT ID NCT07215949

Recruiting now Disease control Sponsor: Miriam Freimer Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests a daily injection called zilucoplan in 15 people hospitalized with severe myasthenia gravis (MG) flare-ups. The goal is to see if the drug can quickly improve daily living activities, like breathing and swallowing, within two weeks. Participants receive the injections for 12 weeks, and researchers track their progress for about 18 weeks total.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Zilucoplan (a drug given as daily injections under the skin)
What this could lead to: If it works, this could provide a new treatment option for severe myasthenia gravis flare-ups, helping people recover faster and avoid prolonged hospital stays.
What could go wrong: This is a small, early-phase trial with only 15 participants, so results may not apply to everyone. The drug may not improve symptoms significantly, and daily injections can be inconvenient or cause side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for GENERALIZED MYASTHENIA GRAVIS (GMG) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

myasthenia gravis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

GENERALIZED MYASTHENIA GRAVIS (GMG)

Contacts and locations

Locations

The Ohio State University
RECRUITING

Columbus, Ohio, 43210, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.